Triglyceride-glucose index in the prediction of new-onset arthritis in the general population aged over 45: the first longitudinal evidence from CHARLS

Liu, Yang; Yao, Junjie; Xue, Xiaona; Lv, Yanan; Guo, Sheng; Wei, PeiDong

doi:10.1186/s12944-024-02070-8

Cited by 3 publications

(1 citation statement)

References 54 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent article found the (TyG) index is considered a marker for predicting new arthritis in people aged more than 45. 21 …”

Section: Introductionmentioning

confidence: 99%

Lipocalin-2 as a marker of inflammation, bone density, and triglyceride-glucose index for new-onset arthritis patients in Mosul, Iraq

Saadon,

Allwsh

2024

Qatar Medical Journal

View full text Add to dashboard Cite

Objective: Lipocalin-2 is an acute phase-associated adipokine that can serve as an inflammatory and biomarker indicator of cartilage deterioration in osteoarthritis. However, its role in the musculoskeletal system remains not fully understood. Hence, this study aimed to evaluate lipocalin-2 and its relationship with markers of inflammation (Interferon-gamma, ESR, and CRP), bone density (vitamin D3 and calcium), and the triglyceride-glucose index in new-onset arthritis patients in Mosul, Iraq. Methods: This study included 125 participants aged 20 to 65, divided into two groups. The Arthritis Patient Group comprised 70 participants (37 females and 33 males) attending the Bone Diseases Consultation Unit at the Ibn Sina Teaching Hospital in Mosul, Iraq. The Control Group comprised 31 females and 24 males. Ethical approval was obtained from the Iraqi Ministry of Health - Nineveh Health (No. 2022095). Commercial ELISA kits were used to measure serum lipocalin-2, Interferon-gamma, ESR, and CRP as inflammation markers, vitamin D3, and calcium as bone density markers. Moreover, the Triglyceride Glucose (TYG) Index was evaluated. Results: The findings revealed a significant increase in lipocalin-2 levels in males compared to females, with LCN-2 increasing with age. Arthritis patients showed a significant increase (72%) in lipocalin-2 levels. Inflammatory indicators (erythrocyte sedimentation rate, C-reactive protein, interferon-gamma) displayed significant increases (46%, 1200%, and 581%, respectively). Glucose (23%), triglycerides (71%), and TYG index (21%) also exhibited significant increases. Meanwhile, bone density indicators (vitamin D3 and calcium) found a significant decrease (53% and 20%, respectively) in arthritis patients. Linear correlation coefficient (R) analysis revealed a significant positive relationship between lipocalin-2 and indicators of inflammation, glucose, TG, and TYG index. Conclusion: This study’s findings suggest that LCN-2 serum levels were higher in patients with new-onset arthritis than in controls in Mosul, and LCN-2 serum increased in males compared with females and getting older serum LCN-2 increased for the patients and control groups. Furthermore, a significant correlation was found between the Triglyceride Glucose Index, which measures metabolic disorders, and serum LCN-2 levels and inflammatory indicators in new-onset arthritis patients in Mosul, Iraq.

show abstract

“…A recent article found the (TyG) index is considered a marker for predicting new arthritis in people aged more than 45. 21 …”

Section: Introductionmentioning

confidence: 99%

Lipocalin-2 as a marker of inflammation, bone density, and triglyceride-glucose index for new-onset arthritis patients in Mosul, Iraq

Saadon,

Allwsh

2024

Qatar Medical Journal

View full text Add to dashboard Cite

show abstract

Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions

Halabitska,

Babinets,

Oksenych

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Diabetes mellitus (DM) and osteoarthritis (OA) are prevalent chronic conditions with shared pathophysiological links, including inflammation and metabolic dysregulation. This study investigates the potential impact of insulin, metformin, and GLP-1-based therapies on OA progression. Methods involved a literature review of clinical trials and mechanistic studies exploring the effects of these medications on OA outcomes. Results indicate that insulin, beyond its role in glycemic control, may modulate inflammatory pathways relevant to OA, potentially influencing joint health. Metformin, recognized for its anti-inflammatory properties via AMPK activation, shows promise in mitigating OA progression by preserving cartilage integrity and reducing inflammatory markers. GLP-1-based therapies, known for enhancing insulin secretion and improving metabolic profiles in DM, also exhibit anti-inflammatory effects that may benefit OA by suppressing cytokine-mediated joint inflammation and supporting cartilage repair mechanisms. Conclusions suggest that these medications, while primarily indicated for diabetes management, hold therapeutic potential in OA by targeting common underlying mechanisms. Further clinical trials are warranted to validate these findings and explore optimal therapeutic strategies for managing both DM and OA comorbidities effectively.

show abstract

Insulin Resistance Treatment with Balanced Personalized Nutrition to Improve Insulin Sensitivity for Prediabetes Remission and Diabetes Type 2 Reversal with Reduction of Risks for Related Chronic Disease

2024

JNFST

View full text Add to dashboard Cite

Insulin sensitivity, as a key measure of metabolic health and hormonal balance, plays a crucial role in metabolic disease with impaired insulin signaling also described as insulin resistance (Zhao et al., 2023). The problem of insulin resistance as a hormonal imbalance due to a changed metabolism is gaining increasing international attention and can be referred to as new epidemic of the 21st century (Zyoud et al., 2022). Insulin resistance affects an estimated 40% of people aged 18–48. Half of the affected people are not overweight (Parcha et al., 2022).

show abstract

Triglyceride-glucose index in the prediction of new-onset arthritis in the general population aged over 45: the first longitudinal evidence from CHARLS

Cited by 3 publications

References 54 publications

Lipocalin-2 as a marker of inflammation, bone density, and triglyceride-glucose index for new-onset arthritis patients in Mosul, Iraq

Lipocalin-2 as a marker of inflammation, bone density, and triglyceride-glucose index for new-onset arthritis patients in Mosul, Iraq

Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions

Insulin Resistance Treatment with Balanced Personalized Nutrition to Improve Insulin Sensitivity for Prediabetes Remission and Diabetes Type 2 Reversal with Reduction of Risks for Related Chronic Disease

Contact Info

Product

Resources

About